Israeli startup Nobio received approval from the US Food and Drug Administration (FDA) for its Infinix advanced dental restoratives called Flowable Composite and Bulk Fill Flow Composite, used to treat tooth decay by filling cavities with material designed to prevent bacterial infections. The products are now cleared to market, the company announced last week.
White fillings used today primarily because they match the color of the tooth prior to decay, are typically less resistant to bacteria than the metallic fillings of the past. Nobio has developed a white filling that matches the tooth and is microbial resistant.
The products use the company’s patented nanomaterial technology to convert materials into anti-microbials and prevent bacteria from colonizing and forming biofilm on surfaces like teeth, Nobio says.
The technology will help fight bacterial infectious diseases, which the company says are the third deadliest disease group globally.
Established in 2015, the Petah Tikva-based company’s founders include Prof. Ervin Weiss, an oral rehabilitation specialist and the dean of the School of Dental Medicine at the Tel Aviv University and Julia Rothman. The technology is a spin-off from Weiss’s academic research at the School of Dental Medicine at Hadassah Medical Center in Jerusalem.
Nobio said it is currently negotiating with distributors and manufacturers and plans to announce its first commercial partnerships later this year.
At the end of July, Nobio closed a $3.6 million funding round led by aMoon Fund and Dr. Ole Jensen, a surgeon and dentist and co-founder of ClearChoice, the largest US network of dental implant clinics, recently acquired by Sun Capital.